HER2 Negative Breast Cancer Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzho

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, HER2 Negative Breast Cancer pipeline constitutes 70+ key companies continuously working towards developing 75+ HER2 Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"HER2 Negative Breast Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HER2 Negative Breast Cancer Market.

The HER2 Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the HER2 Negative Breast Cancer Pipeline Report: https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel HER2 Negative Breast Cancer treatment therapies with a considerable amount of success over the years.
• HER2 Negative Breast Cancer companies working in the treatment market are , and others, are developing therapies for the HER2 Negative Breast Cancer treatment
• Emerging HER2 Negative Breast Cancer therapies in the different phases of clinical trials are- , and others are expected to have a significant impact on the HER2 Negative Breast Cancer market in the coming years.
• In December 2023, Puma Biotechnology, a biopharmaceutical company headquartered in the United States, has introduced the blueprint for the Phase II PUMA-ALI-1201 clinical trial, targeting the use of alisertib in addressing HER2-negative, hormone receptor-positive metastatic breast cancer. After discussions with the US Food and Drug Administration (FDA), the company is set to initiate a study combining alisertib with endocrine therapy for patients with chemotherapy-naïve breast cancer.
• On January 27, 2023, The FDA granted approval for elacestrant (marketed as Orserdu) to treat postmenopausal women or adult men diagnosed with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that showed progression after receiving at least one line of endocrine therapy.
• In January 2023, The European Union (EU) has granted approval for Daiichi Sankyo and AstraZeneca's ENHERTU® (trastuzumab deruxtecan) as a standalone treatment meant for adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer. This approval is specifically for individuals who have undergone prior chemotherapy in the metastatic setting or have experienced disease recurrence either during or within six months after concluding adjuvant chemotherapy.
• In January 2023, Gilead Sciences, Inc. revealed that the European Medicines Agency (EMA) has accepted a Type II variation Marketing Authorization Application (MAA) for Trodelvy (sacituzumab govitecan-hziy). This application pertains to the treatment of adult patients dealing with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer. These patients have undergone endocrine-based therapy and received a minimum of two additional systemic therapies in the metastatic setting.

HER2 Negative Breast Cancer Overview
HER2-negative breast cancer refers to a subtype of breast cancer that does not overexpress the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a protein that promotes the growth of cancer cells, and when breast cancer cells have an overabundance of this protein, it's referred to as HER2-positive breast cancer.

Get a Free Sample PDF Report to know more about HER2 Negative Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging HER2 Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:
• ER-PROTAC: EnhancedBio Inc.
• RLY-2608: Relay Therapeutics, Inc.
• PRT2527: Prelude Therapeutics
• EP0062: Ellipses Pharma
• BPI-1178: Beta Pharma
• CX-2009: CytomX Therapeutics
• Z-endoxifen: Atossa Therapeutics, Inc
• AZD9833: AstraZeneca
• GDC-9545: Roche
• Gedatolisib: Celcuity, Inc.
• BGB-290: BeiGene
• OP-1250: Olema Pharmaceuticals, Inc.
• AZD9833: AstraZeneca
• ADG106: Adagene Inc
• Dato-DXd: Daiichi Sankyo, Inc.
• HRS8807: Shanghai Hengrui Pharmaceutical Co.
• Ipatasertib: Genentech

HER2 Negative Breast Cancer Route of Administration
HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

HER2 Negative Breast Cancer Molecule Type
HER2 Negative Breast Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

HER2 Negative Breast Cancer Pipeline Therapeutics Assessment
• HER2 Negative Breast Cancer Assessment by Product Type
• HER2 Negative Breast Cancer By Stage and Product Type
• HER2 Negative Breast Cancer Assessment by Route of Administration
• HER2 Negative Breast Cancer By Stage and Route of Administration
• HER2 Negative Breast Cancer Assessment by Molecule Type
• HER2 Negative Breast Cancer by Stage and Molecule Type
DelveInsight's HER2 Negative Breast Cancer Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further HER2 Negative Breast Cancer product details are provided in the report. Download the HER2 Negative Breast Cancer pipeline report to learn more about the emerging HER2 Negative Breast Cancer therapies at:
https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the HER2 Negative Breast Cancer Therapeutics Market include:
Key companies developing therapies for HER2 Negative Breast Cancer are - Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., Modra Pharmaceuticals, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., MedImmune LLC, QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer, andn others.

HER2 Negative Breast Cancer Pipeline Analysis:
The HER2 Negative Breast Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Negative Breast Cancer Treatment.
• HER2 Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HER2 Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Negative Breast Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about HER2 Negative Breast Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

HER2 Negative Breast Cancer Pipeline Market Drivers
• HER2 protein is considered a relevant biomarker for treatment, growing prevalence of Breast Cancer are some of the important factors that are fueling the HER2 Negative Breast Cancer Market.

HER2 Negative Breast Cancer Pipeline Market Barriers
• However, poor understanding in the context of breast cancer subtype, lack of research in identification of factors involved in resistance and other factors are creating obstacles in the HER2 Negative Breast Cancer Market growth.

Scope of HER2 Negative Breast Cancer Pipeline Drug Insight
• Coverage: Global
• Key HER2 Negative Breast Cancer Companies: , and others
• Key HER2 Negative Breast Cancer Therapies: , and others
• HER2 Negative Breast Cancer Therapeutic Assessment: HER2 Negative Breast Cancer current marketed and HER2 Negative Breast Cancer emerging therapies
• HER2 Negative Breast Cancer Market Dynamics: HER2 Negative Breast Cancer market drivers and HER2 Negative Breast Cancer market barriers

Request for Sample PDF Report for HER2 Negative Breast Cancer Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. HER2 Negative Breast Cancer Report Introduction
2. HER2 Negative Breast Cancer Executive Summary
3. HER2 Negative Breast Cancer Overview
4. HER2 Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5. HER2 Negative Breast Cancer Pipeline Therapeutics
6. HER2 Negative Breast Cancer Late Stage Products (Phase II/III)
7. HER2 Negative Breast Cancer Mid Stage Products (Phase II)
8. HER2 Negative Breast Cancer Early Stage Products (Phase I)
9. HER2 Negative Breast Cancer Preclinical Stage Products
10. HER2 Negative Breast Cancer Therapeutics Assessment
11. HER2 Negative Breast Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. HER2 Negative Breast Cancer Key Companies
14. HER2 Negative Breast Cancer Key Products
15. HER2 Negative Breast Cancer Unmet Needs
16 . HER2 Negative Breast Cancer Market Drivers and Barriers
17. HER2 Negative Breast Cancer Future Perspectives and Conclusion
18. HER2 Negative Breast Cancer Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

HER2 Negative Breast Cancer Market https://www.delveinsight.com/report-store/her2-negative-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'HER2 Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

HER2 Negative Breast Cancer Epidemiology https://www.delveinsight.com/report-store/her2-negative-breast-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'HER2 Negative Breast Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.